Search Results - "TYNDALE, R. F"

Genomic Medicine, Precision Medicine, Personalized Medicine: What's in a Name? by Roden, D M, Tyndale, R F

“…This issue of Clinical Pharmacology & Therapeutics is devoted to genomic medicine, and a reader may reasonably ask what we mean when we use those words. In the…”
Get full text

Association of Nicotine Metabolite Ratio and CYP2A6 Genotype With Smoking Cessation Treatment in African‐American Light Smokers by Ho, MK, Mwenifumbo, JC, Al Koudsi, N, Okuyemi, KS, Ahluwalia, JS, Benowitz, NL, Tyndale, RF

“…Cytochrome P450 2A6 (CYP2A6) is the main nicotine (NIC)‐metabolizing enzyme in humans. We investigated the relationships between CYP2A6 genotype, baseline…”
Get full text

Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age by Desta, Z, Kreutz, Y, Nguyen, A T, Li, L, Skaar, T, Kamdem, L K, Henry, N L, Hayes, D F, Storniolo, A M, Stearns, V, Hoffmann, E, Tyndale, R F, Flockhart, D A

“…The associations between plasma letrozole concentrations and CYP2A6 and CYP3A5 genetic variants were tested in the Exemestane and Letrozole Pharmacogenomics…”
Get full text

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy by MALAIYANDI, V, LERMAN, C, BENOWITZ, N. L, JEPSON, C, PATTERSON, F, TYNDALE, R. F

“…We investigated the effect of slow metabolism of nicotine, predicted by CYP2A6 genotypes resulting in less than or equal to 50% activity, on baseline smoking…”
Get full text

Designer Drugs 2.0 by Huestis, MA, Tyndale, RF

“…This “Designer Drugs 2.0” issue of Clinical Pharmacology & Therapeutics focuses on novel psychoactive substances, primarily cannabinoids and cathinones, and…”
Get full text

Association of CHRNA5-A3-B4 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers by Zhu, A Z X, Zhou, Q, Cox, L S, David, S P, Ahluwalia, J S, Benowitz, N L, Tyndale, R F

“…Associations between CHRNA5‐A3‐B4 variants and smoking behaviors exist; however, the association with smoking abstinence is less understood, particularly that…”
Get full text

CYP2B6 and Bupropion's Smoking-Cessation Pharmacology: The Role of Hydroxybupropion by Zhu, A Z X, Cox, L S, Nollen, N, Faseru, B, Okuyemi, K S, Ahluwalia, J S, Benowitz, N L, Tyndale, R F

“…Bupropion is indicated to promote smoking cessation. Animal studies suggest that the pharmacologic activity of bupropion can be mediated by its major…”
Get full text

Biomarkers for Smoking Cessation by Bough, K J, Lerman, C, Rose, J E, McClernon, F J, Kenny, P J, Tyndale, R F, David, S P, Stein, E A, Uhl, G R, Conti, D V, Green, C, Amur, S

“…One way to enhance therapeutic development is through the identification and development of evaluative tools such as biomarkers. This review focuses on…”
Get full text

The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response by Giacomini, K M, Brett, C M, Altman, R B, Benowitz, N L, Dolan, M E, Flockhart, D A, Johnson, J A, Hayes, D F, Klein, T, Krauss, R M, Kroetz, D L, McLeod, H L, Nguyen, A T, Ratain, M J, Relling, M V, Reus, V, Roden, D M, Schaefer, C A, Shuldiner, A R, Skaar, T, Tantisira, K, Tyndale, R F, Wang, L, Weinshilboum, R M, Weiss, S T, Zineh, I

“…The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range of research interests, but all attempting to…”
Get full text

Cannabinoids: Friend or foe? by Le Foll, B, Tyndale, RF

“…This issue of Clinical Pharmacology & Therapeutics focuses on cannabinoids. Our understanding of these interesting endogenous and synthetic compounds, and…”
Get full text

Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction by Ho, M K, Goldman, D, Heinz, A, Kaprio, J, Kreek, M J, Li, M D, Munafò, M R, Tyndale, R F

“…Drug addiction remains a substantial health issue with limited treatment options currently available. Despite considerable advances in the understanding of…”
Get full text

Pharmacogenomics at the Tipping Point: Challenges and Opportunities by Roden, DM, Tyndale, RF

Get full text

Genetic and Pharmacokinetic Determinants of Response to Transdermal Nicotine in White, Black, and Asian Nonsmokers by Dempsey, D A, St.Helen, G, Jacob III, P, Tyndale, R F, Benowitz, N L

“…The aim of the study was to examine genetic, pharmacokinetic, and demographic factors that influence sensitivity to nicotine in never‐smokers. Sixty…”
Get full text

Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment by Jukić, M M, Opel, N, Ström, J, Carrillo-Roa, T, Miksys, S, Novalen, M, Renblom, A, Sim, S C, Peñas-Lledó, E M, Courtet, P, Llerena, A, Baune, B T, de Quervain, D J, Papassotiropoulos, A, Tyndale, R F, Binder, E B, Dannlowski, U, Ingelman-Sundberg, M

“…The polymorphic CYP2C19 enzyme metabolizes psychoactive compounds and is expressed in the adult liver and fetal brain. Previously, we demonstrated that the…”
Get full text

Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys by Ferguson, C S, Miksys, S, Palmour, R M, Tyndale, R F

“…In primates, nicotine is metabolically inactivated in the liver by CYP2A6 and possibly CYP2B6. Changes in the levels of these two enzymes may affect nicotine…”
Get more information

CYP2A6 Genotype but not Age Determines Cotinine Half-Life in Infants and Children by Dempsey, D A, Sambol, N C, Jacob III, P, Hoffmann, E, Tyndale, R F, Fuentes-Afflick, E, Benowitz, N L

“…The formation of cotinine, the main proximate metabolite and a biomarker of nicotine exposure, is mediated primarily by cytochrome P450 (CYP)2A6. Our aim was…”
Get full text

Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism by Al Koudsi, N., Tyndale, R. F.

“…Human cytochrome P4502B6 (CYP2B6) is predominantly expressed in the liver and it plays a major role in the metabolism of several therapeutically important…”
Get full text

Toward Personalized Therapy for Smoking Cessation: A Randomized Placebo-controlled Trial of Bupropion by Patterson, F, Schnoll, RA, Wileyto, EP, Pinto, A, Epstein, LH, Shields, PG, Hawk, LW, Tyndale, RF, Benowitz, N, Lerman, C

“…We examined whether a pretreatment phenotypic marker of nicotine metabolism rate (NMR) predicts successful smoking cessation with bupropion. Smokers (N = 414)…”
Get full text

A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes by Messina, E S, Tyndale, R F, Sellers, E M

“…Nicotine is primarily metabolized to cotinine by cytochromes P450 (CYPs). The degree of variation in the metabolism of nicotine to cotinine and the relative…”
Get more information

Genetic Variation in Nicotine Metabolism Predicts the Efficacy of Extended-Duration Transdermal Nicotine Therapy by Lerman, C, Jepson, C, Wileyto, E P, Patterson, F, Schnoll, R, Mroziewicz, M, Benowitz, N, Tyndale, R F

“…In a placebo‐controlled trial, we examined the efficacy of a 6‐month (“extended”) transdermal nicotine therapy vs. the 8‐week (“standard”) therapy in 471…”
Get full text